An Imperial-led project to translate new medical technologies into clinical solutions has received £5m of government funding. The Imperial grant forms part of a £67m investment in 14 collaborative projects between universities and other partners to drive forward world-class university commercialisation across the country.
The investment, made through Research England’s Connecting Capability Fund, will support the MedTech SuperConnector (MTSC) – an ambitious programme which challenges early career researchers to turn their discoveries into new diagnostic tools, medical devices and digital healthcare solutions.
Physically located across three wet-lab incubators in central London, including the Imperial White City Incubator, the MTSC will build upon the College’s vibrant entrepreneurial ecosystem and commercialisation expertise as well as those of seven partner institutions: Queen Mary University of London, Bucks New University, The Francis Crick Institute, Royal College of Art, Royal College of Music, Institute of Cancer Research and Royal Veterinary College.
Professor Nick Jennings, Imperial College Vice-Provost (Research & Enterprise) said: “Imperial has a proud history of taking research out of the lab and into the world. We are constantly thinking about where the next innovation like penicillin, IVF or the i-Knife might come from. The MedTech SuperConnerctor will create a critical mass of brilliants minds, working across institutions to develop new technologies, tools and digital solutions to healthcare challenges.” Read the full story here.
Translation of medical innovations into the clinic is one of the primary objectives of our BRC. The Imperial College Corporate Partnership team within the Faculty of Medicine supports BRC scientists and clinical academics by promoting BRC research in the pharmaceutical, device and equipment manufacturing sectors, to connect and develop collaborations with industry based on mutual scientific interest.
The launch event for the MTSC is taking place on 25th June 7-9pm – find out more here.